St. Jude Medical president & CEO Dan Starks says that rival Medtronic’s failed renal denervation study is not reason to stop pursuing the technology in treatment of hypertension.
St. Jude Medical CEO Daniel Starks remains steadfast in his pursuit of renal denervation in treatment of hypertension, despite the high-profile clinical trial flop suffered just last week by rival medtech titan Medtronic (NYSE:MDT).
St. Jude will continue with its renal denervation initiatives and Starks still sees the technology as a potential winner, he told an audience today at the J.P. Morgan Healthcare conference in San Francisco.
